[Federal Register Volume 85, Number 38 (Wednesday, February 26, 2020)]
[Notices]
[Page 11085]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03832]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Strategic 
Business Initiatives Unit, Office of the Chief Operating Officer, CDC, 
pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--RFA-PS-20-001, Evaluation of New 
HIV Testing Technologies in Clinical Settings with High HIV Incidence.
    Date: June 9, 2020
    Time: 10:00 a.m.-5:00 p.m., (EDT)
    Place: Teleconference, Centers for Disease Control and Prevention, 
Room 1080, 8 Corporate Square Blvd., Atlanta, GA 30329.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, CDC, 1600 Clifton Road, NE, Mailstop US8-1, 
Atlanta, Georgia 30329, (404) 718-8833, [email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-03832 Filed 2-25-20; 8:45 am]
BILLING CODE 4163-18-P